



PEPGEN ADVOCACY 4TH QUARTER NEWSLETTER

A quarterly newsletter for the patient advocacy organizations and communities engaged with PepGen

DUCHENNE MUSCULAR DYSTROPHY

- PepGen is pleased to announce that we have successfully dosed the first person in the CONNECT1-EDO51 study. Read more [here](#).
 - Preliminary data for the safety, exon 51 skipping and dystrophin production is expected in mid-2024 for the 5mg/kg cohort.
- PepGen also anticipates initiating CONNECT2-EDO51, a Phase 2, multinational, randomized, double-blind placebo-controlled multiple ascending dose (MAD) study in 2024.
- PepGen presented on our DMD program at Defeat Duchenne Canada's 2023 Family Forum Weekend, linked [here](#).
- To learn more about CONNECT1-EDO51 study, please visit our clinicaltrials.gov or email clinicaltrials@pepgen.com

MYOTONIC DYSTROPHY TYPE 1

- PepGen announced the first person dosed in the Phase 1, FREEDOM-DM1 clinical trial of PGN-EDODM1 for myotonic dystrophy type 1 (DM1) in December 2023.
 - FREEDOM-DM1 will enroll approximately 24 adults with DM1.
 - The primary objective of the study is to understand safety and tolerability of PGN-EDODM1 after a single dose.
 - PepGen will also look at the amount of drug in muscle, and measures of potential efficacy. Read more [here](#).
 - To learn more about FREEDOM-DM1, please visit clinicaltrials.gov or email clinicaltrials@pepgen.com
- PepGen received regulatory clearance to evaluate PGN-EDODM1 in people living with DM1 from the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA). FREEDOM-DM1 also received regulatory clearance in the US and Canada.

PATIENT ADVOCACY HIGHLIGHTS

DM1 HIGHLIGHT-



In November, PepGen had the privilege of meeting Jeannine, a community member and Myotonic Dystrophy Foundation Support Group Facilitator living with DM1. Jeannine told her story and shared her perspective on living with DM1 during a lunch and learn, leaving an incredible impact on our staff.



NEW YEAR, NEW COMMUNITY PAGE!

Visit PepGen's updated [website](#) and visit the [Community](#) page to see our new look and explore all things Patient Advocacy, including our Community Stories.



We wish you a bright 2024 and are excited to continue to partner with and learn from the neuromuscular disorder community.

HOLIDAY HIGHLIGHT-

The PepGen office had a special visitor this past holiday season! Our new office elf, affectionally named Peppy, joined us from the North Pole with her puppy Oligo, to spread holiday cheer and help the Patient Advocacy team this past month.

